Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

About this Publication
Title
Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years.
Pubmed ID
11189688 (View this publication on the PubMed website)
Publication
Control Clin Trials. 2000 Dec; Volume 21 (Issue 6 Suppl): Pages 356S-378S
Authors

Simpson NK, Johnson CC, Ogden SL, Gamito E, Trocky N, McGuire C, Martin J, Barrow S, Lamerato L, Flickinger LM, Broski KG, Engelhard D, Hilke C, Bonk J, Gahagan B, Gren LH, Childs J, Lappe K, Fouad M, Thompson J, Sullivan D, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team

Abstract

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial has a total enrollment goal of almost 150,000 participants. These participants are being recruited at ten screening centers across the United States. All screening centers tested recruitment methodologies during a 1-year pilot phase. The main phase of recruitment was planned to take place over a 3-year period. The majority of participants are being recruited during the main phase of the study. Each of the screening centers tailors recruitment to its individual catchment area. Recruitment strategies in the PLCO trial are described. As the trial began, several protocol changes were made to help to increase enrollment. The National Cancer Institute (NCI) initiated recruitment efforts at the national level. The individual screening centers describe some of the specific recruitment experiences encountered. As the study progressed, the NCI implemented special initiatives to increase the enrollment of minority participants.

Related CDAS Studies